Chronic pain, fibromyalgia, and long COVID

Abstract

Chronic pain is a common problem in rheumatology. A distinction is made between nociceptive pain and nociplastic pain. Nociceptive pain is, for example, mechanistically explained by persistent inflammation. Neuropathic pain is caused by nerve damage of various possible causes. In contrast, nociplastic pain is not due to tissue damage or a lesion in the somatosensory nervous system-at least not with the currently available techniques. Nociplastic pain is based on an altered perception of pain through modulation of stimulus processing. The concept of central sensitization, together with other neurobiological and psychosocial mechanisms, is considered to be the best explanation for such pain conditions. The syndrome of fibromyalgia (FM), considered to be due to central sensitization, plays a major role in rheumatology-both in terms of differential diagnosis and because the management of inflammatory rheumatic diseases can be made more difficult by the simultaneous presence of FM. During the coronavirus pandemic, persistent pain syndromes with similarities to FM were described following a COVID-19 infection. There is a growing scientific controversy as to whether the so-called long COVID syndrome (LCS) is a separate entity or just a variant of FM.

Keywords

SARS-CoV-2 / COVID-19 / central sensitization / nociplastic pain / neuropathic pain

References

[1] ICD-11 coding tool [Internet]. World Health Organization. [cited 2024 Nov 15] Available from: https://icd.who.int/ct11/icd11_mms/en/release1.

[2] Saxena A, Chansoria M, Tomar G, Kumar A. Myofascial pain syndrome: an overview. J Pain Palliat Care Pharmacother. 2015; 29: 16-21.

[3] Kosek E, Cohen M, Baron R, Gebhart GF, Mico J, Rice ASC, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016; 157: 1382-6.

[4] Kosek E, Clauw D, Nijs J, Baron R, Gilron I, Harris RE, et al. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain. 2021; 162: 2629-34.

[5] Fitzcharles M, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021; 397: 2098-110.

[6] Regierer AC, Hasseli R, Schäfer M, Hoyer BF, Krause A, Lorenz H, et al. TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open. 2021; 7: e001896.

[7] Specker C, Aries P, Braun J, Burmester G, Fischer-Betz R, Hasseli R, et al. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. Z Rheumatol. 2021; 80: 33-48.

[8] Clauw DJ, Calabrese L. Rheumatology and Long COVID: lessons from the study of fibromyalgia. Ann Rheum Dis. 2024; 83: 136-8.

[9] Calabrese LH. Long COVID in inflammatory rheumatic diseases-what’s in a name? Lancet Rheumatol. 2023; 5: e364- 5.

[10] Mariette X. Long COVID: a new word for naming fibromyalgia? Ann Rheum Dis. 2024; 83: 12-4.

[11] Wolfe F, Clauw DJ, Fitzcharles M, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010; 62: 600-10.

[12] Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006; 22: 1911-20.

[13] Häuser W, Ablin J, Fitzcharles M, Littlejohn G, Luciano JV, Usui C, et al. Fibromyalgia. Nat Rev Dis Primers. 2015; 1: 15022.

[14] Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020; 16: 645-60.

[15] Häuser W, Brähler E, Ablin J, Wolfe F. Modified 2016 American College of Rheumatology Fibromyalgia Criteria, the Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks-American Pain Society Pain Taxonomy, and the Prevalence of Fibromyalgia. Arthritis Care Res (Hoboken). 2021; 73: 617-25.

[16] Wolfe F, Butler SH, Fitzcharles M, Häuser W, Katz RL, Mease PJ, et al. Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria. Scand J Pain. 2019; 20: 77-86.

[17] Baraliakos X, Regel A, Kiltz U, Menne H, Dybowski F, Igelmann M, et al. Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis. Rheumatology (Oxford). 2018; 57: 1541-7.

[18] Chaabo K, Chan E, Garrood T, Rutter-Locher Z, Vincent A, Galloway J, et al. Pain sensitisation and joint inflammation in patients with active rheumatoid arthritis. RMD Open. 2024; 10: e003784.

[19] Moltó A, Etcheto A, Gossec L, Boudersa N, Claudepierre P, Roux N, et al. Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers’ effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis. 2018; 77: 533-40.

[20] Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol. 1996; 23: 1407-17.

[21] Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations, Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington (DC): National Academies Press (US); 2015.

[22] Lim E, Ahn Y, Jang E, Lee S, Lee S, Son C. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med. 2020; 18: 100.

[23] Malkova AM, Shoenfeld Y. Autoimmune autonomic nervous system imbalance and conditions: Chronic fatigue syndrome, fibromyalgia, silicone breast implants, COVID and post-COVID syndrome, sick building syndrome, post-orthostatic tachycardia syndrome, autoimmune diseases and autoimmune/inflammatory syndrome induced by adjuvants. Autoimmun Rev. 2023; 22: 103230.

[24] Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, et al.; Dubbo Infection Outcomes Study Group. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006; 333: 575.

[25] Kupferschmitt A, Jöbges M, Randerath J, Hinterberger T, Loew TH, Köllner V. Attention deficits and depressive symptoms improve differentially after rehabilitation of post-COVID condition - A prospective cohort study. J Psychosom Res. 2023; 175: 111540.

[26] Kupferschmitt A, Langheim E, Tüter H, Etzrodt F, Loew TH, Köllner V. First results from post-COVID inpatient rehabilitation. Front Rehabil Sci. 2023; 3: 1093871.

[27] Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023; 21: 133-46. Erratum in: Nat Rev Microbiol. 2023; 21:408.

[28] Mohabbat AB, Mohabbat NML, Wight EC. Fibromyalgia and Chronic Fatigue Syndrome in the Age of COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2020; 4: 764-6.

[29] Calabrese LH, Mease PJ. Improving the nosology of Long COVID: it is not so simple. Ann Rheum Dis. 2024; 83: 9-11.

[30] Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021; 8: 130-40. Erratum in: Lancet Psychiatry. 2021; 8:e1.

[31] Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023; 380: e072529.

[32] Fernández-de-Las-Peñas C, Torres-Macho J, Ruiz-Ruigómez M, Arrieta-Ortubay E, Rodríguez-Rebollo C, Akasbi-Moltalvo M, et al. Presence of SARS-CoV-2 RNA in COVID-19 survivors with post-COVID symptoms 2 years after hospitalization: The VIPER study. J Med Virol. 2024; 96: e29676.

[33] Geng LN, Bonilla H, Hedlin H, Jacobson KB, Tian L, Jagannathan P, et al. Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial. JAMA Intern Med. 2024; 184: 1024-34. Erratum in: JAMA Intern Med. 2024; 184:1137.

[34] Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023; 623: 139-48.

[35] Talla A, Vasaikar SV, Szeto GL, Lemos MP, Czartoski JL, MacMillan H, et al. Persistent serum protein signatures define an inflammatory subcategory of long COVID. Nat Commun. 2023; 14: 3417.

[36] Bodansky A, Wang C, Saxena A, Mitchell A, Kung AF, Takahashi S, et al. Autoantigen profiling reveals a shared post-COVID signature in fully recovered and long COVID patients. JCI Insight. 2023; 8: e169515.

[37] Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022; 23: 210-6.

[38] Altmann DM, Reynolds CJ, Joy G, Otter AD, Gibbons JM, Pade C, et al. Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity. Nat Commun. 2023; 14: 5139.

[39] Matta J, Wiernik E, Robineau O, Carrat F, Touvier M, Severi G, et al. Santé, Pratiques; Relations et Inégalités Sociales en Population Générale Pendant la Crise COVID-19-Sérologie (SAPRIS-SERO) Study Group. Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic. JAMA Intern Med. 2022;182:19-25. Erratum in: JAMA Intern Med. 2022;182:1. Erratum in: JAMA Intern Med. 2022;182:579.

[40] Scherlinger M, Felten R, Gallais F, Nazon C, Chatelus E, Pijnenburg L, et al. Refining “Long-COVID’’ by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection. Infect Dis Ther. 2021; 10: 1747-63.

[41] Jin H, Li M, Jeong E, Castro-Martinez F, Zuker CS. A body-brain circuit that regulates body inflammatory responses. Nature. 2024; 630: 695-703.

[42] Kachaner A, Lemogne C, Dave J, Ranque B, Broucker Td, Meppiel E. Somatic symptom disorder in patients with post-COVID-19 neurological symptoms: a preliminary report from the somatic study (Somatic Symptom Disorder Triggered by COVID-19). J Neurol Neurosurg Psychiatry. 2022; 93: 1174-80.

[43] Reme B, Gjesvik J, Magnusson K. Predictors of the post-COVID condition following mild SARS-CoV-2 infection. Nat Commun. 2023; 14: 5839.

[44] Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022; 13: 3528.

[45] Oh TK, Park HY, Song IA. Risk of psychological sequelae among coronavirus disease-2019 survivors: a nationwide cohort study in South Korea. Depress Anxiety. 2021; 38: 247-54.

[46] Mosch B, Hagena V, Herpertz S, Diers M. Adverse effects of the COVID-19 pandemic on fibromyalgia patients in Germany: a longitudinal investigation including pre-pandemic data of pain and health-related outcomes. Clin Exp Rheumatol. 2023; 41: 1301-9.

[47] Fraterman I, Reijers ILM, Dimitriadis P, Broeks A, Gonzalez M, Menzies AMM, et al. Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma. Nat Med. 2023; 29: 3090-9.

[48] Goldstein DS. Post-COVID dysautonomias: what we know and (mainly) what we don’t know. Nat Rev Neurol. 2024; 20: 99-113.

[49] Fedorowski A, Fanciulli A, Raj SR, Sheldon R, Shibao CA, Sutton R. Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden. Nat Rev Cardiol. 2024; 21: 379-95.

[50] Appelman B, Charlton BT, Goulding RP, Kerkhoff TJ, Breedveld EA, Noort W, et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat Commun. 2024; 15: 17.

[51] Vivaldi G, Pfeffer PE, Talaei M, Basera TJ, Shaheen SO, Martineau AR. Long-term symptom profiles after COVID-19 vs other acute respiratory infections: an analysis of data from the COVIDENCE UK study. EClinicalMedicine. 2023; 65: 102251.

[52] Archambault PM, Rosychuk RJ, Audet M, Hau JP, Graves L, Décary S, et al.; Canadian Critical Care Trials Group investigators; Network of Canadian Emergency Researchers; Canadian Critical Care Trials Group investigators. Post-COVID-19 condition symptoms among emergency department patients tested for SARS-CoV-2 infection. Nat Commun. 2024; 15: 8449.

[53] Llàdser A, Montesó-Curto P, López C, Rosselló L, Lear S, Toussaint L, et al. Multidisciplinary rehabilitation treatments for patients with fibromyalgia: a systematic review. Eur J Phys Rehabil Med. 2022; 58: 76-84.

[54] Gendreau RM, McCracken LM, Williams DA, Luciano JV, Dai Y, Vega N, et al. Self-guided digital behavioural therapy versus active control for fibromyalgia (PROSPER-FM): a phase 3, multicentre, randomised controlled trial. Lancet. 2024; 404: 364-74.

[55] Wang C, Schmid CH, Fielding RA, Harvey WF, Reid KF, Price LL, et al. Effect of tai chi versus aerobic exercise for fibromyalgia: comparative effectiveness randomized controlled trial. BMJ. 2018; 360: k851.

[56] Wang C, Schmid CH, Rones R, Kalish R, Yinh J, Goldenberg DL, et al. A randomized trial of tai chi for fibromyalgia. N Engl J Med. 2010; 363: 743-54.

[57] Andrés-Rodríguez L, Borràs X, Feliu-Soler A, Pérez-Aranda A, Rozadilla-Sacanell A, Montero-Marin J, et al. Immune-inflammatory pathways and clinical changes in fibromyalgia patients treated with Mindfulness-Based Stress Reduction (MBSR): A randomized, controlled clinical trial. Brain Behav Immun. 2019; 80: 109-19.

[58] Pérez-Aranda A, Feliu-Soler A, Montero-Marín J, García-Campayo J, Andrés-Rodríguez L, Borràs X, et al. A randomized controlled efficacy trial of mindfulness-based stress reduction compared with an active control group and usual care for fibromyalgia: the EUDAIMON study. Pain. 2019; 160: 2508-23.

[59] Haugmark T, Hagen KB, Smedslund G, Zangi HA. Mindfulness- and acceptance-based interventions for patients with fibromyalgia - A systematic review and meta-analyses. PLoS One. 2019; 14: e0221897.

[60] Sheldon RS, 2nd BPG, Olshansky B, Shen W, Calkins H, Brignole M, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015; 12: e41-63.

[61] Arnold AC, Okamoto LE, Diedrich A, Paranjape SY, Raj SR, Biaggioni I, Gamboa A. Low-dose propranolol and exercise capacity in postural tachycardia syndrome: a randomized study. Neurology. 2013; 80: 1927-33.

[62] Fedorowski A. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. J Intern Med. 2019; 285: 352-66.

[63] Kocyigit BF, Akyol A. The relationship between COVID-19 and fibromyalgia syndrome: prevalence, pandemic effects, symptom mechanisms, and COVID-19 vaccines. Clin Rheumatol. 2022; 41: 3245-52.

[64] Arienti C, Cordani C, Lazzarini SG, Del Furia MJ, Negrini S, Kiekens C. Fatigue, post-exertional malaise and orthostatic intolerance: a map of Cochrane evidence relevant to rehabilitation for people with post COVID-19 condition. Eur J Phys Rehabil Med. 2022; 58: 857-63.

[65] Høeg TB, Ladhani S, Prasad V. How methodological pitfalls have created widespread misunderstanding about long COVID. BMJ Evid Based Med. 2024; 29: 142-6.

[66] Saunders C, Sperling S, Bendstrup E. A new paradigm is needed to explain long COVID. Lancet Respir Med. 2023; 11: e12-3.

[67] Landewé RBM. Correspondence on‘Long COVID: a new word for naming fibromyalgia?’ by Mariette. Ann Rheum Dis. 2024; 83: e15.

[68] Mariette X. Response to: Correspondence on ‘Long COVID: a new word for naming fibromyalgia?’ by Mariette. Ann Rheum Dis. 2024; 83: e16.

[69] Bair MJ, Krebs EE. Fibromyalgia. Ann Intern Med. 2020; 172: ITC33-48.

[70] Clauw DJ. From fibrositis to fibromyalgia to nociplastic pain: how rheumatology helped get us here and where do we go from here? Ann Rheum Dis. 2024; 83: 1421-7.